Phase III Clinical Trial Comparing the Safety, Efficacy, and Immunogenicity of Recombinant Anti-interleukin-6 Receptor Humanized Monoclonal Antibody Injection in Combination With Methotrexate and Jamelor ® in the Treatment of Moderate to Severe Rheumatoid Arthritis

NCT06048224 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

669

Enrollment

INDUSTRY

Sponsor class

Conditions

Moderate to Severe Active Rheumatoid Arthritis

Interventions

DRUG: HS628+MTX
DRUG: Actemra +MTX

Sponsor

Zhejiang Hisun Pharmaceutical Co. Ltd.